Supplementary Material

Supplementary Table1 Univariate analysis for cofilin expression before imatinib therapy.

variable	OR	p-value
Gender	0.458	0.123
Age	1.023	0.204
WBC ($\times 10^9$/L)	0.994	0.006[*]
Hb (g/L)	0.979	0.015[*]
PLT ($\times 10^9$/L)	0.997	0.065
Peripheral blood eosinophils (%)	0.913	0.12
Peripheral blood basophils (%)	0.991	0.079
Bone marrow blasts (%)	0.953	0.042[*]
Bone marrow eosinophils (%)	5.821	0.213
Bone marrow basophils (%)	4.943	0.291
BCR-ABL	0.992	0.271

* indicates statistical significance, OR: ods ratio

Supplementary Table2 Multivariate analysis for cofilin expression before imatinib therapy.

variable	β	OR	p value
WBC	-0.014	0.986	0.033[*]
PLT	-0.006	0.994	0.028[*]

* indicates statistical significance, OR: ods ratio

Supplementary Figure


Supplementary Figure1

The CFL1 expression level of each patient was tested twice using Quantitative RT-PCR before and after 3 months imatinib therapy.

Supplementary Figure2 The real-time PCR dissociation curve of CFL1

Supplementary Figure3 The real-time PCR dissociation curve of GAPDH

Supplementary Figure4 The real-time PCR amplification efficiency for CFL1

Supplementary Figure5 The real-time PCR amplification efficiency for GAPDH